{"id":"https://openalex.org/W7224117244","doi":"https://doi.org/10.1177/13524585261496124","title":"Ocrelizumab treatment and disability progression in non-Hispanic Black and Hispanic or Latino individuals with relapsing multiple sclerosis: A post hoc analysis of the OPERA I and II trials","display_name":"Ocrelizumab treatment and disability progression in non-Hispanic Black and Hispanic or Latino individuals with relapsing multiple sclerosis: A post hoc analysis of the OPERA I and II trials","publication_year":2026,"publication_date":"2026-10-28","ids":{"openalex":"https://openalex.org/W7224117244","doi":"https://doi.org/10.1177/13524585261496124","pmid":"https://pubmed.ncbi.nlm.nih.gov/42949019"},"language":"en","primary_location":{"id":"doi:10.1177/13524585261496124","doi":"https://doi.org/10.1177/13524585261496124","is_oa":true,"landing_page_url":"https://doi.org/10.1177/13524585261496124","pdf_url":null,"source":{"id":"https://openalex.org/S136332993","display_name":"Multiple Sclerosis Journal","issn_l":"1352-4585","issn":["1352-4585","1477-0970"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1177/13524585261496124","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063222574","display_name":"Lilyana Amezcua","orcid":"https://orcid.org/0000-0003-1542-7819","observed_orcids":["https://orcid.org/0000-0003-1542-7819"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lilyana Amezcua","raw_affiliation_strings":["Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, USA"],"raw_orcid":"https://orcid.org/0000-0003-1542-7819","affiliations":[{"raw_affiliation_string":"Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, USA","institution_ids":["https://openalex.org/I1174212"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051451145","display_name":"Devi Sai Sri Kavya Boorgu","orcid":"https://orcid.org/0000-0002-5580-743X","observed_orcids":["https://orcid.org/0000-0002-5580-743X"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Devi Sai Sri Kavya Boorgu","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002941966","display_name":"Jake D. Oxendine","orcid":"https://orcid.org/0000-0002-9201-4586","observed_orcids":["https://orcid.org/0000-0002-9201-4586"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jake Oxendine","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA, USA"],"raw_orcid":"https://orcid.org/0000-0002-9201-4586","affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032245024","display_name":"Ibraheem Abioye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ibraheem Abioye","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041979519","display_name":"Tushar Bhangale","orcid":"https://orcid.org/0000-0002-8233-9977","observed_orcids":["https://orcid.org/0000-0002-8233-9977"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tushar Bhangale","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073323104","display_name":"Christopher T. Harp","orcid":"https://orcid.org/0000-0001-7000-8743","observed_orcids":["https://orcid.org/0000-0001-7000-8743"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Harp","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101872642","display_name":"Chien\u2010Ju Lin","orcid":"https://orcid.org/0000-0001-5224-3539","observed_orcids":["https://orcid.org/0000-0001-5224-3539"]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Chien-Ju Lin","raw_affiliation_strings":["Roche Products Ltd, Welwyn Garden City, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Products Ltd, Welwyn Garden City, UK","institution_ids":["https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008709977","display_name":"Nicolas B. Strauli","orcid":"https://orcid.org/0000-0001-8575-006X","observed_orcids":["https://orcid.org/0000-0001-8575-006X"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicolas Strauli","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025704380","display_name":"Akshaya Ramesh","orcid":"https://orcid.org/0000-0003-0205-0688","observed_orcids":["https://orcid.org/0000-0003-0205-0688"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Akshaya Ramesh","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020903163","display_name":"Bruce Cree","orcid":"https://orcid.org/0000-0001-7689-2533","observed_orcids":["https://orcid.org/0000-0001-7689-2533"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce A. C. Cree","raw_affiliation_strings":["Department of Neurology, Weill Institute for Neuroscience, University of California, San Francisco, CA, USA"],"raw_orcid":"https://orcid.org/0000-0001-7689-2533","affiliations":[{"raw_affiliation_string":"Department of Neurology, Weill Institute for Neuroscience, University of California, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080632445","display_name":"Mitzi Joi Williams","orcid":"https://orcid.org/0000-0001-6979-1101","observed_orcids":["https://orcid.org/0000-0001-6979-1101"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mitzi J. Williams","raw_affiliation_strings":["Joi Life Wellness MS Neurology Center, Smyrna, GA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Joi Life Wellness MS Neurology Center, Smyrna, GA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050326447","display_name":"Xiaoming Jia","orcid":"https://orcid.org/0000-0002-5104-5431","observed_orcids":["https://orcid.org/0000-0002-5104-5431"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoming Jia","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA, USA"],"raw_orcid":"https://orcid.org/0000-0002-5104-5431","affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5063222574"],"corresponding_institution_ids":["https://openalex.org/I1174212"],"apc_list":{"value":4400,"currency":"USD","value_usd":4400},"apc_paid":{"value":4400,"currency":"USD","value_usd":4400},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.8672549,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"13524585261496124","last_page":"13524585261496124"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.9359999895095825},{"id":"https://openalex.org/keywords/ocrelizumab","display_name":"ocrelizumab","score":1.0},{"id":"https://openalex.org/keywords/disability-progression","display_name":"disability progression","score":0.9290000200271606},{"id":"https://openalex.org/keywords/racial-and-ethnic-disparities","display_name":"racial and ethnic disparities","score":0.9819999933242798},{"id":"https://openalex.org/keywords/non-hispanic-black-patients","display_name":"non-Hispanic Black patients","score":0.921999990940094},{"id":"https://openalex.org/keywords/hispanic-patients","display_name":"Hispanic patients","score":0.9909999966621399},{"id":"https://openalex.org/keywords/interferon-beta-1a","display_name":"interferon beta-1a","score":0.8600000143051147},{"id":"https://openalex.org/keywords/cd19-b-cells","display_name":"CD19+ B cells","score":0.9129999876022339},{"id":"https://openalex.org/keywords/genetic-ancestry","display_name":"genetic ancestry","score":0.9120000004768372},{"id":"https://openalex.org/keywords/african-ancestry","display_name":"African ancestry","score":0.5910000205039978},{"id":"https://openalex.org/keywords/european-ancestry","display_name":"European ancestry","score":0.6499999761581421},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.5989999771118164},{"id":"https://openalex.org/keywords/b-cell-depletion","display_name":"B-cell depletion","score":0.5139999985694885},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.5669999718666077}],"concepts":[{"id":"https://openalex.org/C2778843634","wikidata":"https://www.wikidata.org/wiki/Q2013780","display_name":"Ocrelizumab","level":4,"score":0.8522999882698059},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.8026000261306763},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7914999723434448},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.6438000202178955},{"id":"https://openalex.org/C2908698914","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta-1a","level":4,"score":0.5353999733924866},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4528999924659729},{"id":"https://openalex.org/C2780892749","wikidata":"https://www.wikidata.org/wiki/Q929518","display_name":"Expanded Disability Status Scale","level":3,"score":0.39730000495910645},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.38960000872612},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.36899998784065247},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3188000023365021},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3165999948978424},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.3156000077724457},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3149999976158142},{"id":"https://openalex.org/C2779668873","wikidata":"https://www.wikidata.org/wiki/Q6693756","display_name":"Lower risk","level":3,"score":0.3068000078201294},{"id":"https://openalex.org/C2781028063","wikidata":"https://www.wikidata.org/wiki/Q338802","display_name":"Clinically isolated syndrome","level":3,"score":0.30169999599456787},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.30160000920295715},{"id":"https://openalex.org/C137403100","wikidata":"https://www.wikidata.org/wiki/Q41710","display_name":"Ethnic group","level":2,"score":0.288100004196167},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2655999958515167},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.2565999925136566},{"id":"https://openalex.org/C2781222467","wikidata":"https://www.wikidata.org/wiki/Q338460","display_name":"Negroid","level":3,"score":0.2540999948978424},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.25110000371932983}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1177/13524585261496124","doi":"https://doi.org/10.1177/13524585261496124","is_oa":true,"landing_page_url":"https://doi.org/10.1177/13524585261496124","pdf_url":null,"source":{"id":"https://openalex.org/S136332993","display_name":"Multiple Sclerosis Journal","issn_l":"1352-4585","issn":["1352-4585","1477-0970"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis Journal","raw_type":"journal-article"},{"id":"pmid:42949019","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42949019","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple sclerosis (Houndmills, Basingstoke, England)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1177/13524585261496124","doi":"https://doi.org/10.1177/13524585261496124","is_oa":true,"landing_page_url":"https://doi.org/10.1177/13524585261496124","pdf_url":null,"source":{"id":"https://openalex.org/S136332993","display_name":"Multiple Sclerosis Journal","issn_l":"1352-4585","issn":["1352-4585","1477-0970"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0},{"id":"https://metadata.un.org/sdg/10","display_name":"Reduced inequalities","score":0.7578999996185303}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W775956452","https://openalex.org/W1540979859","https://openalex.org/W1937030621","https://openalex.org/W1982303250","https://openalex.org/W2020134202","https://openalex.org/W2024520434","https://openalex.org/W2062684133","https://openalex.org/W2079478300","https://openalex.org/W2081756011","https://openalex.org/W2104549677","https://openalex.org/W2104797721","https://openalex.org/W2119444539","https://openalex.org/W2169804206","https://openalex.org/W2170115175","https://openalex.org/W2277731492","https://openalex.org/W2538361155","https://openalex.org/W2558170458","https://openalex.org/W2561881161","https://openalex.org/W2565433170","https://openalex.org/W2602301651","https://openalex.org/W2895801590","https://openalex.org/W2982676376","https://openalex.org/W3119663458","https://openalex.org/W3163593027","https://openalex.org/W3201965895","https://openalex.org/W4205556878","https://openalex.org/W4211048507","https://openalex.org/W4224951282","https://openalex.org/W4225006257","https://openalex.org/W4225308128","https://openalex.org/W4376617977","https://openalex.org/W4377565097","https://openalex.org/W4387261809","https://openalex.org/W4400724355","https://openalex.org/W4409640299","https://openalex.org/W4412492484"],"related_works":["https://openalex.org/W7171803328","https://openalex.org/W4394599727","https://openalex.org/W4367302941","https://openalex.org/W4316506655","https://openalex.org/W3163593027","https://openalex.org/W3199314722","https://openalex.org/W4414168990","https://openalex.org/W4401344157","https://openalex.org/W6941212238","https://openalex.org/W2468099764"],"abstract_inverted_index":{"Background:":[0],"Racial":[1],"and":[2,16,25,87,105,182,211,235,252],"ethnic":[3],"disparities":[4],"are":[5],"evident":[6],"in":[7,151,204,218,271],"multiple":[8,31,42,110,124,155,187,223,257,275],"sclerosis.":[9,32],"Objectives:":[10],"To":[11],"assess":[12],"whether":[13],"disease":[14,261],"progression":[15,85,147,216,262,269],"treatment":[17,101],"response":[18],"differ":[19],"between":[20,94],"non-Hispanic":[21,26,50,62,103,119,131,226,247,250],"Black":[22,51,104,181,227,251],"or":[23,61,167,281],"Hispanic/Latino":[24,56,106,183,236,253],"White":[27,63,120,248],"people":[28,39,107,121,152,184,220,254,272],"with":[29,40,108,118,122,153,157,185,197,221,246,255,273],"relapsing":[30,41,109,123,154,186,222,256,274],"Methods:":[33],"This":[34],"post":[35],"hoc":[36],"analysis":[37],"included":[38],"sclerosis":[43,111,125,156,188,258,276],"from":[44],"ocrelizumab":[45,200],"trials":[46],"(NCT01247324/NCT01412333)":[47],"self-reporting":[48],"as":[49],"(":[52,57,64,75,207],"n":[53,58,65,76],"=":[54,59,66,77,136,165,233,242],"65),":[55],"213),":[60],"1350).":[67],"Genetic":[68],"ancestry":[69,169],"was":[70,149],"analyzed":[71],"for":[72],"consenting":[73],"participants":[74],"1138).":[78],"In":[79,97],"addition,":[80],"24-week":[81,114],"composite":[82,213,266],"confirmed":[83,145,214,267],"disability":[84,146,215,268],"risk":[86,116,148,217,270],"CD19":[88,192],"+":[89,193],"B":[90,194,202],"cells":[91,203],"were":[92],"compared":[93,117],"subgroups.":[95],"Results:":[96],"the":[98],"interferon":[99,198],"beta-1a":[100],"arm,":[102],"had":[112,189],"increased":[113,190],"cCDP":[115],"(hazard":[126,160,170,228,237],"ratio":[127],"(95%":[128],"confidence":[129],"interval)":[130],"Black:":[132],"3.0":[133],"(1.4\u20136.5);":[134],"p":[135,141,164,174,208,232,241],"0.005;":[137],"Hispanic/Latino:":[138],"2.3":[139],"(1.6\u20133.4);":[140],"<":[142,175,209],"0.001).":[143],"Composite":[144],"greater":[150],"higher":[158,260],"African":[159],"ratio:":[161,171,229,238],"4.4":[162],"(1.7\u201311.2);":[163],"0.002)":[166],"Americas":[168],"5.8":[172],"[2.7\u201312.4];":[173],"0.001)":[176,210],"than":[177],"European":[178],"ancestry.":[179,283],"Non-Hispanic":[180],"baseline":[191],"cells.":[195],"Compared":[196,245],"beta-1a,":[199],"reduced":[201,265],"all":[205,219],"groups":[206],"decreased":[212],"sclerosis,":[224],"including":[225],"0.41":[230],"(0.13\u20131.29);":[231],"0.13)":[234],"0.38":[239],"(0.20\u20130.72);":[240],"0.003).":[243],"Conclusion:":[244],"people,":[249],"showed":[259],"risk.":[263],"Ocrelizumab":[264],"regardless":[277],"of":[278],"race,":[279],"ethnicity,":[280],"genetic":[282]},"counts_by_year":[],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2026-10-29T00:00:00"}